Disease · MONDO_0016367
Trials62
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
1 to 20 of 62
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00106184 | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | Phase 2 | 200 | 2015-03-04 | Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00979654 | A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis | Phase 2 | 118 | 2016-08-23 | Systemic Lupus Erythematosus | SIFALIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02728752 | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) | Phase 3 | 95 | 2021-04-21 | Dermatomyositis | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
| NCT03181893 | A Study In Adults With Moderate To Severe Dermatomyositis | Phase 2 | 75 | 2023-09-14 | Dermatomyositis | DAZUKIBART | Its record names the disease | ClinicalTrials.gov |
| NCT03981744 | A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments | Phase 3 | 51 | 2024-05-13 | Polymyositis, Dermatomyositis | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04999020 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | Phase 2/3 | 38 | 2024-12-06 | Dermatomyositis | RAVULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02043548 | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis | Phase 2 | 36 | 2020-10-30 | Dermatomyositis, Polymyositis | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00651040 | Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM | Phase 3 | 31 | 2016-05-12 | Polymyositis, Dermatomyositis | METHOTREXATE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT02612857 | Trial of IMO-8400 in Adult Patients With Dermatomyositis | Phase 2 | 30 | 2019-10-10 | Dermatomyositis | BAZLITORAN | Its record names the disease | ClinicalTrials.gov |
| NCT00504348 | Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus | Phase 2/3 | 25 | 2020-03-24 | Interstitial Pneumonitis, Polymyositis, Dermatomyositis | PREDNISOLONE, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT04033926 | A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis | Phase 2 | 25 | 2024-01-03 | Polymyositis, Dermatomyositis | ZETOMIPZOMIB | Its record names the disease | ClinicalTrials.gov |
| NCT05192200 | An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study | Phase 2 | 24 | 2025-02-06 | Dermatomyositis | DAZUKIBART | Its record names the disease | ClinicalTrials.gov |
| NCT02466243 | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | Phase 2 | 22 | 2023-01-19 | Dermatomyositis | LENABASUM | Its record names the disease | ClinicalTrials.gov |
| NCT01148810 | Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis | Phase 2 | 18 | 2019-04-25 | Polymyositis, Dermatomyositis | SIPONIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT04628936 | Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. | Phase 2 | 18 | 2024-06-05 | Polymyositis, Dermatomyositis | ZETOMIPZOMIB | Its record names the disease | ClinicalTrials.gov |
| NCT02029274 | Safety and Efficacy of BAF312 in Dermatomyositis | Phase 2 | 17 | 2019-01-15 | Active Dermatomyositis | SIPONIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT02347891 | Belimumab in Idiopathic Inflammatory Myositis | Phase 2/3 | 17 | 2024-02-09 | Myositis | BELIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00112385 | A Pilot Study of Etanercept in Dermatomyositis | Phase 1 | 16 | 2011-06-21 | Dermatomyositis | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03267277 | Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis | Phase 2/3 | 15 | 2024-02-26 | Dermatomyositis, Idiopathic Inflammatory Myopathies | SODIUM THIOSULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01906372 | Acthar in Treatment of Refractory Dermatomyositis and Polymyositis | Phase 2 | 12 | 2017-08-02 | Dermatomyositis, Polymyositis | CORTICOTROPIN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016367/trials